Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 12—December 2020
Research Letter

Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020

Paul K.S. Chan, Grace LuiComments to Author , Asmaa Hachim, Ronald L.W. Ko, Siaw S. Boon, Timothy Li, Niloufar Kavian, Fion Luk, Zigui Chen, Emily M. Yau, Kin H. Chan, Chi-hang Tsang, Samuel M.S. Cheng, Daniel K.W. Chu, Ranawaka A.P.M. Perera, Wendy C.S. Ho, Apple C.M. Yeung, Chit Chow, Leo L.M. Poon, Sophie A. Valkenburg, David S.C. Hui, and Malik PeirisComments to Author 
Author affiliations: The Chinese University of Hong Kong, Hong Kong, China (P.K.S. Chan, G. Lui, S.S. Boon, T. Li, F. Luk, Z. Chen, W.C.S. Ho, A.C.M. Yeung, C. Chow, D.S.C. Hui); The University of Hong Kong, Hong Kong (A. Hachim, R.L.W. Ko, N. Kavian, E.M. Yau, K.H. Chan, C. Tsang, S.M.S. Cheng, D.K.W. Chu, R.A.P.M. Perera, L.L.M. Poon, S.A. Valkenburg, M. Peiris)

Main Article

Figure

Timeline of primary infection and reinfection with severe acute respiratory syndrome coronavirus 2, Hong Kong, August, 2020. A) Onset. B) Discharge. C) Clinical follow-up. D) Mandatory testing. Black font indicates data from this investigation; red font indicates data from To et al. (6). Ct, cycle threshold; ELISA-N, enzyme linked immunosorbent assay for N protein; LIPS, luciferase immune precipitation assay; PRNT50, 50% plaque reduction neutralization test titer; RBD, receptor binding domain; RT-PCR, reverse transcription PCR; S/CO, ratio of optical density readings of sample divided by cutoff (ratio of >1.4 considered positive); sVNT, surrogate virus neutralization test; +, positive; –, negative; +/–, borderline.

Figure. Timeline of primary infection and reinfection with severe acute respiratory syndrome coronavirus 2, Hong Kong, August, 2020. A) Onset. B) Discharge. C) Clinical follow-up. D) Mandatory testing. Black font indicates data from this investigation; red font indicates data from To et al. (6). Ct, cycle threshold; ELISA-N, enzyme linked immunosorbent assay for N protein; LIPS, luciferase immune precipitation assay; PRNT50, 50% plaque reduction neutralization test titer; RBD, receptor binding domain; RT-PCR, reverse transcription PCR; S/CO, ratio of optical density readings of sample divided by cutoff (ratio of >1.4 considered positive); sVNT, surrogate virus neutralization test; +, positive; –, negative; +/–, borderline.

Main Article

References
  1. Kiyuka  PK, Agoti  CN, Munywoki  PK, Njeru  R, Bett  A, Otieno  JR, et al. Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. J Infect Dis. 2018;217:1728–39. DOIPubMedGoogle Scholar
  2. Callow  KA. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. J Hyg (Lond). 1985;95:173–89. DOIPubMedGoogle Scholar
  3. Perera  RA, Mok  CK, Tsang  OT, Lv  H, Ko  RL, Wu  NC, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25:2000421. DOIPubMedGoogle Scholar
  4. Hachim  A, Kavian  N, Cohen  CA, Chin  AWH, Chu  DKW, Mok  CKP, et al. ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. [Erratum in: Nat Immunol. 2020 Aug 27; Epub ahead of print]. Nat Immunol. 2020 Aug 17 [Epub ahead of print].PubMedGoogle Scholar
  5. Addetia  A, Crawford  KHD, Dingens  A, Zhu  H, Roychoudhury  P, Huang  ML, et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. J Clin Microbiol. 2020;Aug 21:JCM.02107-20. DOIPubMedGoogle Scholar
  6. To  KK, Hung  IF, Ip  JD, Chu  AW, Chan  WM, Tam  AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020;ciaa1275. DOIPubMedGoogle Scholar
  7. Tan  CW, Chia  WN, Qin  X, Liu  P, Chen  MI, Tiu  C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:1073–8. DOIPubMedGoogle Scholar
  8. Li  JY, Liao  CH, Wang  Q, Tan  YJ, Luo  R, Qiu  Y, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074. DOIPubMedGoogle Scholar

Main Article

Page created: September 18, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external